of determining whether the gene has been transferred into 
important organs, such as the liver or spleen. 
It is important to note that participation in this study will in 
no way alter any of the standard care you (your child) may be 
receiving. There will be no charge to you (your child) or to 
your insurance for any of the tests, procedures or hospital stays 
associated with this study. You will continue to be responsible 
for the cost of other medical care. You (your child) may 
withdraw from this study at any time, and we would continue to 
follow you (your child) as described above without prejudice. You 
(your child) are then free to explore any other treatment 
options, standard or experimental. 
Potential Risks : The specific risks associated with each 
component of this protocol were described above. This protocol 
should be considered as offering no guarantee of direct benefit 
to you (your child) , but posing some risk. In any new form of 
therapy, there may be risks which are unknown or not anticipated. 
Since the vector does not replicate inside the body, we do not 
anticipate that it can alter your sperm/ ova, and therefore we do 
not anticipate that this treatment could adversely affect your 
offspring. Participation in this study will not lower the risk 
of passing Fanconi ' s anemia to your offspring. 
Women of child-bearing potential are advised to use an effective 
method of birth control until the safety of this experimental 
therapy has been fully established. Men are advised to use 
barrier-protection while participating in this study. Females 
must have had a negative pregnancy test within 14 days prior to 
dosing. If you should become pregnant while on this study you 
must inform the investigator immediately. 
Recombinant DNA Research, Volume 19 
[577] 
